Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuPath HealthTSXV:NPTH 39 Earnings Yield (Joel Greenblatt) % is 3.63% as of Jun. 2026. GuruFocus rates TSXV:NPTH with a GF Score™ of 39/100 and a GF Value™ of C$0.25 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 684 Healthcare Providers & Services companies, NeuPath Health ranks better than 51.75% on this metric.
NeuPath Health's Enterprise Value for the quarter that ended in Jun. 2026 was C$47.17 Mil.
NeuPath Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was C$1.71 Mil. NeuPath Health's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 3.63%.
The historical rank and industry rank for NeuPath Health's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
TSXV:NPTH'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -21.08 Med: -4.68 Max: 6.94
Current: 4.13
During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of NeuPath Health was 6.94%. The lowest was -21.08%. And the median was -4.68%.
TSXV:NPTH's Earnings Yield (Joel Greenblatt) % is ranked better than 51.75% of 684
companies
in the Healthcare Providers & Services industry
Industry Median: 3.875
vs TSXV:NPTH: 4.13
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. NeuPath Health's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
NeuPath Health (TSXV:NPTH) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
NeuPath Health Earnings Yield (Joel Greenblatt) % Related Terms
NeuPath Health Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for NeuPath Health's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuPath Health Earnings Yield (Joel Greenblatt) % Chart
For the Medical Care Facilities subindustry, NeuPath Health's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuPath Health Earnings Yield (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NeuPath Health's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where NeuPath Health's Earnings Yield (Joel Greenblatt) % falls into.
NeuPath Health Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
NeuPath Healths Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
NeuPath Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.71 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 3.63% mean?
NeuPath Health (TSXV:NPTH) has a Earnings Yield (Joel Greenblatt) % of 3.63% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on NeuPath Health and its competitors. According to the industry distribution chart, NeuPath Health ranks #330 out of 684 companies in the Healthcare Providers & Services industry, placing it in the top 48.2%.
Is NeuPath Health's Earnings Yield (Joel Greenblatt) % too high?
NeuPath Health's current Earnings Yield (Joel Greenblatt) % is 3.63%. The Healthcare Providers & Services industry median Earnings Yield (Joel Greenblatt) % is 3.88. NeuPath Health's value of 3.63% is 6.3% below this industry median. Based on the distribution chart, NeuPath Health ranks #330 out of 684 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, NeuPath Health has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuPath Health's Earnings Yield (Joel Greenblatt) % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, NeuPath Health ranks #330 out of 684 companies for Earnings Yield (Joel Greenblatt) %. This puts NeuPath Health in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.88. NeuPath Health's value of 3.63% is 6.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median Earnings Yield (Joel Greenblatt) % among Healthcare Providers & Services companies is 3.88, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuPath Health's current Earnings Yield (Joel Greenblatt) % of 3.63% is 6.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on NeuPath Health and its competitors. For the Healthcare Providers & Services industry, the median Earnings Yield (Joel Greenblatt) % is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuPath Health's current Earnings Yield (Joel Greenblatt) % is 3.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuPath Health stock overvalued right now?
Based on GuruFocus' analysis, NeuPath Health (TSXV:NPTH) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.55 — trading 120% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 3.63% and 6.3% below the Healthcare Providers & Services industry median of 3.88. NeuPath Health's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For NeuPath Health (TSXV:NPTH), the current Earnings Yield (Joel Greenblatt) % is 3.63% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuPath Health (TSXV:NPTH) Overvalued in 2026?
Based on GuruFocus' analysis, NeuPath Health stock appears to be overvalued.
The current stock price of C$0.55 is trading 120% above its estimated GF Value™ of C$0.25.
GuruFocus considers NeuPath Health to be Significantly Overvalued.
Key valuation signals for TSXV:NPTH:
Earnings Yield (Joel Greenblatt) %: 3.63%
GF Value™: C$0.25 vs. price of C$0.55 (120% above fair value)
Industry Position: 6.3% below the Healthcare Providers & Services median (#330 of 684)
No single metric tells the full story. See the TSXV:NPTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuPath Health Inc operates an end-to-end, integrated network of healthcare businesses. It utilizes research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by acute and chronic musculoskeletal conditions, including chronic pain, spinal injuries, sports-related injuries, and concussions. It operates an interdisciplinary network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of healthcare providers. Its medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal or back injuries, sports-related injuries, and concussions. The company operates in one industry segment: medical services.
39GF Score
Get the complete analysis for TSXV:NPTH
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:NPTH has been successfully added to your 
